Exploring the role of LPC16:0 in fibromyalgia
A Clinical Approach to Validate the Biological Significance of LPC16:0 as a Discriminating and Pathogenic Biomarker of Fibromyalgia
This study is trying to see how a specific compound called LPC16:0 affects people with fibromyalgia to help find better ways to diagnose and treat the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 245 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Kaohsiung Medical University Chung-Ho Memorial Hospital Academic / other |
| Locations | 1 site (Kaohsiung City) |
| Trial ID | NCT04832100 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the significance of lysophosphatidylcholine (LPC16:0) in patients diagnosed with fibromyalgia, a condition characterized by chronic widespread pain and various comorbidities such as fatigue and anxiety. The study aims to explore the underlying mechanisms of fibromyalgia through advanced metabolomic techniques, which may help identify potential biomarkers for diagnosis and treatment. Participants will be assessed based on their clinical diagnosis and will receive treatments like pregabalin and imipramine as part of their management plan.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals with a clinical diagnosis of fibromyalgia.
Not a fit: Patients with systemic rheumatological disorders, chronic diseases under poor control, or those who are pregnant may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to the identification of biomarkers that improve the diagnosis and treatment of fibromyalgia.
How similar studies have performed: While there have been studies exploring various aspects of fibromyalgia, the specific focus on LPC16:0 and its implications is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1\. Clinical diagnosis of fibromyalgia Exclusion Criteria: 1. Systemic rheumatological or immune disorders (e.g., systemic lupus erythematosus, inflammatory myositis), 2. Systemic use of corticosteroids, 3. Pregnancy, 4. Chronic diseases under poor control 5. Malignancies.
Where this trial is running
Kaohsiung City
- Kaohsiung Medical University Hospital — Kaohsiung City, Taiwan (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.